Write in a clean editor, then format for Cancer immunity in one click — DocuGuru applies the official Springer Nature template with superscript references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Cancer immunity is a peer-reviewed journal published by Springer Nature, covering Immunotherapy and Immune Responses, Immune Cell Function and Interaction, vaccines and immunoinformatics approaches.
| Publisher | Springer Nature |
|---|---|
| Reference style | Superscript numbered (Nature) Superscript — small raised numerals in the text 1. Smith, A., Jones, B. & Lee, C. A representative article title. Cancer immunity 12, 45–58 (2023).
Formats any DOI in Cancer immunity style. No sign-up. |
| Publishes research in | Immunotherapy and Immune Responses Immune Cell Function and Interaction vaccines and immunoinformatics approaches Cancer Immunotherapy and Biomarkers CAR-T cell therapy research |
| ISSN | 1424-9634 |
| h-index | 4 |
| Total citations | 60 |
| Top institutions publishing here | Memorial Sloan Kettering Cancer Center |
| Journal website | www.cancerimmunity.org |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Tumors express tumor-associated antigens (TAAs) and thus should be the object of immune attack. Nonetheless, spontaneous clearance of established tumors is rare. Initial thinking was that lack of TAA-specific immunity was largely passive: tumors did not present enough TAAs, or antigen-presenting cells did not have sufficient stimulatory capacity. Attempts were made to boost TAA-specific immunity…
Recent studies have strongly suggested that regulatory T cells are essential for the maintenance of self-tolerance. In 1995, a major subset of naturally arising regulatory T cells has been identified as CD25+CD4 T cells and has become since a focus of intense investigations. In addition to the control of autoimmunity, these cells have been implicated…
Our ability to simply and rapidly transduce human cells offers novel prospects for the targeting and functional enhancement of tumor-reactive T lymphocytes. Recognition of self tumor antigens is indeed constrained by mechanisms of immune tolerance. Furthermore, tumors exploit a number of mechanisms to elude or derail immunity, including the down-regulation of antigen and/or MHC expression…
The variability of HIV has raised the question of whether T cells raised against one strain can cross-react with another. This is highly pertinent to vaccine design, especially as most vaccines being prepared are B clade and more than 90% of infections worldwide are non-B clade. The clades differ by more than 20% in amino…
GSK Biologicals’ approach is based upon immunizing cancer patients with a vaccine composed of a recombinant MAGE-3-derived protein combined with an immunological adjuvant. Phase I/II clinical trials have been, and are being, performed in various indications, with emphasis upon cutaneous metastatic melanoma and NSCLC. Trials have been conducted to optimize the immune response to the…
